|
| |
| | | 67525 | | 18.03.2020 | | Sanofi-Aventis (Suisse) SA | | | | | | | | | | | | | 07.16.10. | | | | 07.16.10. | | IP |
| | Seq.-No. | Product | Description | Galenic form | ATC-classification | |
|---|
| 01 | Sarclisa 100 mg/5 mL | solution à diluer pour perfusion | Concentrate for infusion (Isatuximabum 100mg / 5ml) | L01FC02 | | | 02 | Sarclisa 500 mg/25 mL | solution à diluer pour perfusion | Concentrate for infusion (Isatuximabum 500mg / 25ml) | L01FC02 | |
|
|
|
